MIB1 and familial pancreatic carcinoma: To elucidate the mechanisms underlying MIB1’s pro‐tumorigenic effects in pancreatic cancer, we performed immunoprecipitation and mass spectrometry to identify binding partners of MIB1 (Fig. S1A,B, and Table S3).